Publications by authors named "Barbara Schauble"

Claim this Profile
T
The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons.
Maria Vassilaki, Jeremiah A Aakre, Walter K Kremers, Michelle M Mielke, Yonas E Geda, Barbara Schauble

J Gerontol A Biol Sci Med Sci· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia.
Maria Vassilaki, Jeremiah A Aakre, Walter K Kremers, Michelle M Mielke, Yonas E Geda, Barbara Schauble

J Am Geriatr Soc· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
Rosebud O Roberts, Jeremiah A Aakre, Walter K Kremers, Maria Vassilaki, David S Knopman, Barbara Schauble

JAMA Neurol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease.
Marwan N Sabbagh, Barbara Schäuble, Keshav Anand, Danielle Richards, Shigeo Murayama

J Alzheimers Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of β-amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts.
Michael L Ganz, Alie F Tawah, Shien Guo, Abhishek S Chitnis, Hedwig Silies

Neurodegener Dis Manag· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
Michael Rösler, Ylva Ginsberg, Torben Arngrim, Marios Adamou, Asko Niemelä

World J Biol Psychiatry· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
Miguel Casas, Michael Rösler, J J Sandra Kooij, Ylva Ginsberg, Josep Antoni Ramos-Quiroga

World J Biol Psychiatry· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic impact of galantamine vs placebo: an analysis based on functional capacity in a Swedish cohort study.
Anders Wimo, Maren Gaudig, Barbara Schäuble, Erik Jedenius

J Med Econ· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial.
J J Sandra Kooij, Michael Rösler, Alexandra Philipsen, Sandra Wächter, Joachim Dejonckheere

BMC Psychiatry· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study.
Zhenxin Zhang, Lu Yu, Maren Gaudig, Barbara Schäuble, Ute Richarz

Neuropsychiatr Dis Treat· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents.
Thomas Küpper, Jan Haavik, Hans Drexler, Josep Antoni Ramos-Quiroga, Detlef Wermelskirchen, Barbara Schauble

Int Arch Occup Environ Health· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
Shane Kavanagh, Bart Van Baelen, Barbara Schäuble

J Alzheimers Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
Jan K Buitelaar, Esther Sobanski, Rolf-Dieter Stieglitz, Joachim Dejonckheere, Sandra Waechter

J Clin Psychiatry· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Christian Wolff, Adam Alfred, Anton Lindermüller, Klaus Rettig, Fritz Mattejat

Curr Med Res Opin· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.
Jan K Buitelaar, Götz-Erik Trott, Maria Hofecker, Sandra Waechter, Joris Berwaerts

Int J Neuropsychopharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Elio Scarpini, Giuseppe Bruno, Giuseppe Zappalà, Marina Adami, Ute Richarz

J Alzheimers Dis· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term assessment of topiramate for epilepsy: an open-label, single-arm, multicentre, prospective study in a naturalistic setting.
Andreas Hufnagel, Andreas Kowalik, Klaus Rettig, Andreas Schreiner, Barbara Schäuble

Clin Drug Investig· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Andreas Kordon, Kirsten Stollhoff, Käte Niederkirchner, Fritz Mattejat, Klaus Rettig

Postgrad Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?
Michael Berek, Andreas Kordon, Ludger Hargarter, Fritz Mattejat, Lara Slawik

Child Adolesc Psychiatry Ment Health· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability of seizure semiology in patients with 2 seizure foci.
Kevin M Rathke, Barbara Schäuble, A James Fessler, Elson L So

Arch Neurol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Käthe Niederkirchner, Lara Slawik, Detlef Wermelskirchen, Klaus Rettig, Barbara Schäuble

Expert Rev Neurother· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.
Jan K Buitelaar, J J Sandra Kooij, J Antoni Ramos-Quiroga, Joachim Dejonckheere, Miguel Casas

Prog Neuropsychopharmacol Biol Psychiatry· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate.
Jean Schoenen, Uwe Reuter, Hans-Christoph Diener, Joop Pfeil, Susanne Schwalen

Cephalalgia· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the unmet treatment need in partial-onset epilepsy: looking beyond seizure control.
Bettina Schmitz, Georgia Montouris, Barbara Schäuble, Sue Caleo

Epilepsia· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seizure and cognitive outcomes in children and adolescents with epilepsy treated with topiramate.
U Brandl, G Kurlemann, B Neubauer, K Rettig, Barbara Schäuble

Neuropediatrics· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis